Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness - Wikidata - thesis-toulmin - TriplyDB

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

http://www.wikidata.org/entity/Q28817181

about

Antiparasitic lethality of sulfonamidebenzamides in kinetoplastids.Meta-transcriptome Profiling of the Human-Leishmania braziliensis Cutaneous Lesion.Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid Transporters in Trypanosoma cruzi High-resolution cryo-EM proteasome structures in drug development.The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery The ubiquitin-conjugating enzyme CDC34 is essential for cytokinesis in contrast to putative subunits of a SCF complex in Trypanosoma brucei.Chagas disease research and development: Is there light at the end of the tunnel?Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.Structure and Biosynthesis of Isatropolones, Bioactive Amine-Scavenging Fluorescent Natural Products from Streptomyces Gö66.Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.Chemotherapy of leishmaniasis: present challenges.Computer-Aided Drug Design Using Sesquiterpene Lactones as Sources of New Structures with Potential Activity against Infectious Neglected Diseases.Activity-based probes for the multicatalytic proteasome.Targeting proteasomes in infectious organisms to combat disease.Recent developments in trans-sialidase inhibitors of Trypanosoma cruzi.Genome-wide and protein kinase-focused RNAi screens reveal conserved and novel damage response pathways in Trypanosoma brucei.Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni.RNAi screening identifies Trypanosoma brucei stress response protein kinases required for survival in the mouse.Molecular diagnostics for Chagas disease: up to date and novel methodologies.Differences in the Detection of BrdU/EdU Incorporation Assays Alter the Calculation for G1, S, and G2 Phases of the Cell Cycle in Trypanosomatids.Cell Cycle Inhibition To Treat Sleeping Sickness Experimental and Clinical Treatment of Chagas Disease: A Review.Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.Genetically Validated Drug Targets in Leishmania; Current Knowledge and Future Prospects.The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.Sulfur-Fluoride Exchange (SuFEx)-Mediated Synthesis of Sterically Hindered and Electron-Deficient Secondary and Tertiary Amides via Acyl Fluoride Intermediates.Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening.Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome.Phenotypic screening approaches for Chagas disease drug discovery.Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.Expanding the toolbox for Trypanosoma cruzi: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localisation and phenotyping.Identification of a novel fused gene family implicates convergent evolution in eukaryotic calcium signaling.Glycosylated metal chelators as anti-parasitic agents with tunable selectivity.Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes.Validation of Babesia proteasome as a drug target Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis

P2860

Q30274930-1AF038F0-4E55-47E6-9E8B-35A41CB7576D Q36133707-42DD4C03-28C7-4A24-A72E-53225C9D31A7 Q36312076-11407FD1-99A7-499E-B3E5-84FE2AEC4A6E Q36392578-0605C15E-DC00-4B47-89A5-1EB332CE9640 Q36395995-98649CAB-DAAC-4D04-AC48-1CBD7D30C216 Q36400535-6EC3DDE0-F8DA-41C8-B110-26ACA10A396C Q37541623-29167610-47E9-47B2-BF66-747D44532878 Q38695331-C28D466F-71F8-4234-85BC-901D60ED0771 Q38928764-51D52A65-30F9-4C27-A1AB-C52F1C068054 Q39003990-687ECB3D-4001-4143-BA7E-02E9A0947313 Q39011875-6C0E4F84-E660-413F-A27B-D63C6FA7D8F1 Q39065488-FA97D66B-F19E-47A7-B0A0-E7705B34C6DF Q39096761-6D35FFE7-FC5F-43CB-A8CB-F320CD5206C8 Q39103077-B67962FC-F9A4-46FB-9160-FC4F7E7478CE Q39111617-CED00011-7143-4FAB-A2FB-DD5EE0518979 Q39492733-8E2986FF-3141-45AE-9E0F-40EEF4053878 Q40045616-C547C75B-EB85-4AF1-A5CC-542F7CCE6A75 Q40124264-FD145E70-2583-432D-83C5-01D45ED88C4F Q40184873-07AD8C86-BFF0-4224-AB4D-0261734F540F Q40308957-FF9A0437-F331-4393-B4FF-CFF44FF114EE Q41676261-473EBA14-2391-4B72-9D84-84E97D81BB93 Q41989175-2E13AE14-5AFE-42E0-90DD-565F1C2CE4D4 Q41990715-CB0D7D50-2234-49C7-8CBB-9AD4B29B7036 Q45305049-5852E2F8-B6BF-4E3E-9D41-9F661BAC2E38 Q46445771-4F0820FD-C162-4047-B4D1-E048004F9AB6 Q47702679-CB67F382-9D28-41FB-9B9C-CABF9D8A64F8 Q48243287-6F923206-C9BA-406F-A930-CD04BF7F44D6 Q48281203-5FC99C9D-42F2-45E0-A06D-6EEF60D1D330 Q48330948-461F3EF8-A236-4456-A3A5-F1AEF3BEC772 Q48340774-3F064093-5C54-4250-A66E-0AF596C8F4BF Q49862753-7C6E1FA4-7A8D-4B7F-9565-655FC2E3A294 Q51730628-2106E876-3D0E-48BF-AAE4-87C6C65366C6 Q52334618-727C7893-E037-43B5-9ACB-2B22EDAFCF34 Q52716173-11E0002E-D216-4829-B3F6-264C1258C41F Q53375546-150D3F3C-2D62-4F28-9707-0143987FDCBE Q53731615-CFE4A509-3D82-4184-A843-DD4AAE7C15F8 Q56346314-C01E95E8-024D-4F35-93AE-D8FD5AF2FD04 Q56362409-CACC7929-D8DA-49B2-BF4E-770F67056134 Q57166879-1E2B2F16-61AF-47D4-AC3F-1F1C223941B6 Q57190987-460CD9A1-2221-4617-B1A8-1979B3B2D8C6

P2860

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

http://www.wikidata.org/entity/Q28817181

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Proteasome inhibition for trea ...... disease and sleeping sickness

@ast

Proteasome inhibition for trea ...... disease and sleeping sickness

@en

type

label

Proteasome inhibition for trea ...... disease and sleeping sickness

@ast

Proteasome inhibition for trea ...... disease and sleeping sickness

@en

prefLabel

Proteasome inhibition for trea ...... disease and sleeping sickness

@ast

Proteasome inhibition for trea ...... disease and sleeping sickness

@en

P1433

Q28817181-FBCE35AA-349F-47C7-95A2-31BEDDBA5A71

P1476

Q28817181-255F3DF8-57ED-4213-8DF1-872ADA778968

P2093

Q28817181-07234CFC-01EA-4A16-AAC4-36DE9D1FED36

Q28817181-14F5EAE3-19DF-4BA6-9AB3-592C6A16425A

Q28817181-2951F907-8753-4944-9909-65E61B6B8AC7

Q28817181-318DB12A-5F73-4F18-864C-A5EBAE678927

Q28817181-48F81040-411F-4FD3-9947-71A21E79070F

Q28817181-49A287C0-7D87-4E84-A395-99F702F918FB

Q28817181-4C7DB0BC-F9B6-4FC3-8763-D961CB681AA2

Q28817181-50B62350-737F-432E-AE5C-2F91C361D2A8

Q28817181-50F9E5B2-AD15-46B5-94B9-6FE57EBF84FA

Q28817181-53EA5D18-BD14-4D3C-9EF5-5C2EA7D90D39

P2860

Q28817181-01C96965-A95E-4FAE-ADEE-56AD2FB7D5E1

Q28817181-052C2759-CB17-4FE4-A62B-D2DD69DF8391

Q28817181-11F27214-DAA1-4897-8F3D-1EEFB096C413

Q28817181-141EAAFD-098E-4F3F-ADBA-EE61DC7F8934

Q28817181-15E0CB51-DF1A-498D-9608-26382687A679

Q28817181-16176308-2EF3-4758-B1CD-D4591AB57B91

Q28817181-1CF9D462-E909-4222-963D-62A3A5035E5B

Q28817181-259B88C2-471A-4489-A78D-10741FF51673

Q28817181-348222E1-3661-4EDC-A9E0-18D0203416F6

Q28817181-36F38560-D2FB-412B-B0CF-64EEE77D1D85

P2888

Q28817181-62BA64E4-4A18-4C9B-8005-5CFBABF04B21

P304

Q28817181-AC4D7C66-9FB0-49A1-AF82-E886E75381AC

P31

Q28817181-8AD9CAB0-D9D8-41DD-971C-03758648BB97

P3181

Q28817181-A4EEBB3D-CAF9-49A2-A4FC-125C4CA91C63

P356

Q28817181-86EF16EE-C5C5-45CC-87F4-6330C1025E20

P407

Q28817181-5A106CD5-2784-48DD-9A0E-AC905DA438C9

P433

Q28817181-7AC090CF-8A6B-4A54-89DE-FF960B409D62

P478

Q28817181-F2F95A7D-0E60-4DC5-84FC-5EE6258CF611

P50

Q28817181-38D2C809-539F-423A-A7E2-9DBB978DA25D

Q28817181-45494F4E-F190-4273-B0B7-F856ED09A516

Q28817181-98F0E5C6-1B1E-456C-8F6B-0C22296FC6BB

Q28817181-B878B8EC-79B0-4A1F-837D-C93445610CFE

P577

Q28817181-E2DD5315-AC5F-4658-AA03-6D193332D48F

P6179

Q28817181-8AED3682-C0D4-421C-9AC8-00657F329916

P698

Q28817181-B0C93958-D2BF-432C-97C6-37EDE40B68B2

P921

Q28817181-095895ED-BEED-4ECD-B784-1A49567734DD

Q28817181-945C04CA-2460-44E8-869A-4DA21A1BDA21

P932

Q28817181-2D209261-5BD6-4478-A5EC-C429087AD25A

P3181

P356

P1433

P1476

Proteasome inhibition for trea ...... disease and sleeping sickness

@en

P2093

Advait S Nagle

http://www.w3.org/2001/XMLSchema#string

Agnes Biggart

http://www.w3.org/2001/XMLSchema#string

Ansgar Brock

http://www.w3.org/2001/XMLSchema#string

Badry Bursulaya

http://www.w3.org/2001/XMLSchema#string

Ben G Wen

http://www.w3.org/2001/XMLSchema#string

Fang Liang

http://www.w3.org/2001/XMLSchema#string

Frantisek Supek

http://www.w3.org/2001/XMLSchema#string

Glen Spraggon

http://www.w3.org/2001/XMLSchema#string

Glenn Federe

http://www.w3.org/2001/XMLSchema#string

Hazel X Y Koh

http://www.w3.org/2001/XMLSchema#string

P2860

The genome of the kinetoplastid parasite, Leishmania major

Combating the next lethal epidemic

GeneDB--an annotation database for pathogens

Chagas disease: an overview of clinical and epidemiological aspects

Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis

In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis

The structure of the mammalian 20S proteasome at 2.75 A resolution

Highly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferase

Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease

A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei

P2888

P304

229-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3513955

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE19339

http://www.w3.org/2001/XMLSchema#string

P407

P433

7619

http://www.w3.org/2001/XMLSchema#string

P478

537

http://www.w3.org/2001/XMLSchema#string

P50

Jeremy C. Mottram

Elmarie Myburgh

Frederick S Buckner

Casey J N Mathison

P577

2016-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036903066

http://www.w3.org/2001/XMLSchema#string

P698

27501246

http://www.w3.org/2001/XMLSchema#string

P921

African trypanosomiasis

P932

5161665

http://www.w3.org/2001/XMLSchema#string